Ahead of Phacilitate’s Advanced Therapies Europe, Join key industry experts to discuss the current state and trajectory of ATMPs in the EU.

As the world has seen seismic shifts in the funding, technical and commercial landscape for cell and gene therapies, it is important to identify Europe’s evolving role in the global ecosystem, how we can establish and shore-up European bioregions that can translate, develop and manufacture the next generation of ATMPs.

This is a must-attend, plenary-level meeting for translational, technical and commercial cell and gene therapy experts.

Agenda

Short intro from Ry Leahy & Ingerid Sorgaard (Phacilitate)

Panel:
Where is Europe in the global standing of cell and gene therapies?
Where are the gaps/what are the core infrastructure needs?
- Technical, analytical and scale needs
- Facility and logistical needs

How do we ensure access for patients with European ATMPs?
- Access through cost reduction
- Ensuring robust supply

What role does Europe play in advancing global ATMPs?